{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toxicity&page=18", "query": { "intervention": "Toxicity", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 8351, "total_pages": 836, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toxicity&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Toxicity&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T09:29:21.892Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00107536", "title": "Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2005-10", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107536" }, { "nct_id": "NCT01432171", "title": "Lacosamide in Preventing Seizures in Participants With Malignant Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "Lacosamide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-07-25", "completion_date": "2017-06-20", "has_results": true, "last_update_posted_date": "2018-12-19", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01432171" }, { "nct_id": "NCT03287271", "title": "ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "VS-6063", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael McHale", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-02-06", "completion_date": "2025-03-12", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03287271" }, { "nct_id": "NCT01660971", "title": "Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IV Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2012-07-30", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660971" }, { "nct_id": "NCT07214532", "title": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Neoplasms", "Carcinoma, Ductal, Breast", "Receptors, Estrogen (for ER-positive Requirement)" ], "interventions": [ { "name": "ctDNA-Guided Treatment Strategy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 725, "start_date": "2026-05-08", "completion_date": "2037-12-30", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07214532" }, { "nct_id": "NCT01158521", "title": "Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Stage I Renal Cell Cancer", "Stage II Renal Cell Cancer", "Stage III Renal Cell Cancer" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2010-06", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2018-09-12", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01158521" }, { "nct_id": "NCT05766371", "title": "Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castrate Resistant Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer", "Prostate Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "177Lu-PSMA-617", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2023-12-15", "completion_date": "2031-05-31", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05766371" }, { "nct_id": "NCT07799571", "title": "Buprenorphine for the Management of Pain in Children With Sickle Cell Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease (SCD)", "Sickle Cell Disease Vaso-occlusive Crisis", "Sickle Cell Anemia Crisis", "Sickle Cell Anemia in Children", "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)", "Sickle Cell Hemoglobin C Disease", "Pain Crisis" ], "interventions": [ { "name": "Buprenorphine Buccal Film [Belbuca]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Natasha Archer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "12 Years to 22 Years" }, "enrollment_count": 25, "start_date": "2026-10", "completion_date": "2032-10", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07799571" }, { "nct_id": "NCT01818063", "title": "Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2013-04-25", "completion_date": "2018-12-10", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania • Reading, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01818063" }, { "nct_id": "NCT02160106", "title": "First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Stage Solid Tumors" ], "interventions": [ { "name": "TEW-7197", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedPacto, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-07-29", "completion_date": "2018-08-28", "has_results": false, "last_update_posted_date": "2019-05-09", "last_synced_at": "2026-10-29T09:29:21.892Z", "location_count": 3, "location_summary": "Durham, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02160106" } ] }